Details
| Stereochemistry | MIXED |
| Molecular Formula | C22H28NO3 |
| Molecular Weight | 354.4626 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CC[N+]1(C)CCCC(C1)OC(=O)C(O)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=WPUKUEMZZRVAKZ-UHFFFAOYSA-N
InChI=1S/C22H28NO3/c1-3-23(2)16-10-15-20(17-23)26-21(24)22(25,18-11-6-4-7-12-18)19-13-8-5-9-14-19/h4-9,11-14,20,25H,3,10,15-17H2,1-2H3/q+1
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14349937 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13192610 |
Primary | Unknown Approved UseUnknown |
||
| Palliative | SINSPASMON Approved UseEffective in the treatment of peptic ulcer and coadjuvant in irritable bowel syndrome, spastic colon, mucosal colitis, acute enterocolitis, colic, pylorus spasm, regurgitation and other functional disorders of the gastrointestinal tract. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. | 2004-06 |
|
| The treatment index of JB 323 (piptal) in peptic ulcer. | 1957-01 |
|
| Peptic ulcer management with JB 323 (piptal) a new anticholinergic. | 1955-03 |
|
| Pharmacologic properties of N-ethyl-3-piperidyl benzilate methobromide (JB-323), a potent antispasmodic agent. | 1954-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13192610
for dog: orally active antispasmodic agent with an atropine-like action
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A03CA09
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
||
|
WHO-VATC |
QA03AB14
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
||
|
WHO-ATC |
A03AB14
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
PIPENZOLATE
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
DTXSID9048481
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
2185
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
33743
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB03838MIG
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
4832
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
RS3K5YXV34
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
13473-38-6
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
DB13844
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
236-748-1
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY | |||
|
100000085306
Created by
admin on Mon Mar 31 19:38:27 GMT 2025 , Edited by admin on Mon Mar 31 19:38:27 GMT 2025
|
PRIMARY |
ACTIVE MOIETY